Abbott Laboratories


Want a discount? Become a member by purchasing Annual Subscription!
SKU: ABT Category:


Abbott Laboratories had a mixed 2020. The company’s medical device sales were badly hit because of the COVID-19 pandemic but the management made the most out of the pandemic situation by successfully rolling out and receiving approval for a wide variety of rapid COVID-19 tests. The COVID-19 diagnostics contributed heavily to the company’s top-line for the year and the testing activity is expected to be strong for 2021. Over and above the COVID-19, the company should see a strong upside from its diabetes and mitral regurgitation devices. Also, medical device sales should see a strong recovery in 2021. Overall, the company is poised for a strong year ahead.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $496 annual subscription!